Cell Membranes as Therapeutic Targets: Implications in Infectious and Metabolic Disorders

Year : 2026 | Volume : 03 | Issue : 01 | Page : 47 53
    By

    Hetvi H. Patel,

  • Hardini P. Chauhan,

  • Maitry H. Rathod,

  • Vaibhavi J. Panchal,

  • Bisojeet R. Khandai,

  1. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  2. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  3. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  4. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  5. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India

Abstract

This is a review of the crucial role played by cell membranes in health and disease with respect to their contribution to infectious and metabolic diseases. Dysfunction of membranes, such as membrane transporter changes and changes in lipid content, has been associated with a variety of diseases, including diabetes, cardiovascular disease, and cancer. The present therapeutic approaches are focused on attacking membrane constituents by disrupting the entry of pathogens or dysfunctional membrane proteins, which have potential as therapies for infections, metabolic disorders, and cancer. Examples are SGLT2 inhibitors to treat diabetes and CCR5 inhibitors to treat HIV. Moreover, nanotechnology, gene editing, and individualized treatment are giving new prospects for more specific and efficient treatment. The applications of membrane-targeted therapies are enormous, and future studies are bound to allow therapeutic agents to be delivered more effectively and produce better treatment results. This paper brings to light the present methods as well as the future perspectives of the membrane-targeted therapies and provides an insight into the potential of the same in the treatment of complex diseases.

Keywords: Ccr5-inhibitors, cell membranes, gene editing, membrane dysfunction, membrane transporters, metabolic disorders, nanotechnology, personalized medicine, SGLT2-inhibitors, therapeutic strategies

[This article belongs to International Journal of Membranes ]

How to cite this article:
Hetvi H. Patel, Hardini P. Chauhan, Maitry H. Rathod, Vaibhavi J. Panchal, Bisojeet R. Khandai. Cell Membranes as Therapeutic Targets: Implications in Infectious and Metabolic Disorders. International Journal of Membranes. 2026; 03(01):47-53.
How to cite this URL:
Hetvi H. Patel, Hardini P. Chauhan, Maitry H. Rathod, Vaibhavi J. Panchal, Bisojeet R. Khandai. Cell Membranes as Therapeutic Targets: Implications in Infectious and Metabolic Disorders. International Journal of Membranes. 2026; 03(01):47-53. Available from: https://journals.stmjournals.com/ijm/article=2026/view=240338


References

1. Li Y, Sun H, Cao D, Guo Y, Wu D, Yang M, et al. Overcoming biological barriers in cancer therapy: Cell membrane-based nanocarrier strategies for precision delivery. Int J Nanomedicine. 2025 Dec 31:3113–45. 2. Kaya S. Cellular structure and function. In: Pathological basis of oral and maxillofacial diseases. 2025 Jan 8. p.51–63. 3. Qiu XY, Sun YK, Gao JQ, Jiang XC. Progress and application of cell membrane engineering in living cell therapy. Biomater Sci. 2025. 4. Liu J, Wang T, Dong J, Lu Y. The blood–brain barriers: Novel nanocarriers for central nervous system diseases. J Nanobiotechnol. 2025 Feb 26;23(1):146. 5. Aljameeli AM, Alsuwayt B, Bharati D, Gohri V, Mohite P, Singh S, et al. Chloride channels and mast cell function: Pioneering new frontiers in IBD therapy. Mol Cell Biochem. 2025 Mar 4:1–9. 6. Cao X, Wang N, Yang M, Zhang C. Lipid accumulation and insulin resistance: Bridging metabolic dysfunction-associated fatty liver disease and chronic kidney disease. Int J Mol Sci. 2025 Jul 20;26(14):6962. 7. Zhang J, Wu S, Xu Y, Zhang L, Cong C, Zhang M, et al. Lipid overload meets S-palmitoylation: A metabolic signalling nexus driving cardiovascular and heart disease. Cell Commun Signal. 2025;23(1):392. 8. Warda M, Tekin S, Gamal M, Khafaga N, Çelebi F, Tarantino G. Lipid rafts: Novel therapeutic targets for metabolic, neurodegenerative, oncological, and cardiovascular diseases. Lipids Health Dis. 2025;24(1):147. 9. Kaur R, Singh S, Sood P, Singh S, Banerjee S, Singh TG. Diabetic cardiomyopathy: Mechanistic insights on molecular pathways and emerging therapeutic approaches. Heart Fail Rev. 2025;30(6):1443–80. 10. Majood M, Rao R. Human milk: Insights on cell composition, organoids and emerging applications. Pediatr Res. 2025. 11. Altan-Bonnet N, Panigrahi M. Nonlytic egress and transmission in the virus world. Annu Rev Biochem. 2025;94:531–60. 12. Kumar D, Gupta V, Tanwar R, Jaiswal NK, Gupta S. Phosphofructokinase-1: A crucial regulator in glycolysis and therapeutic target in cancer progression. In: Gugulothu D, Talegaonkar S, Kumar L, editors. Enzyme based approaches in cancer healthcare management. Singapore: Springer Nature Singapore; 2026. p.57–70. 13. Kumar D, Gupta V, Tanwar R, Jaiswal NK. Revolutionizing diabetic macular edema treatment: FDA approval of Susvimo. SN Compr Clin Med. 2025;7(1):194. 14. Verma DK, Chaudhary S, Sunil S. Investigation of endocytic pathways during entry of RNA viruses reveal novel host proteins as lipid raft dependent endocytosis mediators. Virology. 2025;608:110531. 15. Zhang WZ. Chapter 7 – Pharmacologically targeting caveolae in metabolic diseases. In: De Oliveira MR, editor. Pharmacological targets in metabolic diseases. Academic Press; 2026. p.127–39. 16. Gimeno-Agud H, Díaz-Osorio Y, Oyarzábal A. Biological basis of cell trafficking: A general overview. J Inherit Metab Dis. 2025;48(1):e12839. 17. Bengal E, Aviram S. p38α MAPK regulation of energy metabolism in skeletal muscle offers a therapeutic path for type 2 diabetes. Cells. 2025;14(16):1277. 18. Abdolla N, Narmuratova G, Abdusattarova Y, Kali A, Perfilyeva Y, Ostapchuk Y, et al. The impact of high-fat diet and circadian disruptions on obesity and immune system dysfunction. ES Food Agrofor. 2025;20:1591. 19. Zhang T, Liu Y, Yang Y, Luo J, Hao C. The effect and mechanism of regular exercise on improving insulin impedance: Based on the perspective of cellular and molecular levels. Int J Mol Sci. 2025;26(9):4199. 20. Du J, Shen M, Chen J, Yan H, Xu Z, Yang X, et al. The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: Insights and clinical applications. Front Pharmacol. 2025;15–2024. 21. Akram J, Menezes P, Idris NI, Thomas JE, Darwish R, Tania A, et al. Metabolic stress and adaptation in pancreatic β-cells to hypoxia: Mechanisms, modulators, and implications for transplantation. Cells. 2025;14(24). 22. Kuzu OF, Granerud LJ, Saatcioglu F. Navigating the landscape of protein folding and proteostasis: From molecular chaperones to therapeutic innovations. Signal Transduct Target Ther. 2025 Oct 23;10(1):358. 23. Amissah HA, Likhomanova R, Opoku G, Amissah TA, Balogi Z, Török Z, et al. Plasma membrane epichaperome–lipid interface: Regulating dynamics and trafficking. Cells. 2025 Oct 11;14(20):1582.

Regular Issue Subscription Review Article
Volume 03
Issue 01
Received 01/02/2026
Accepted 02/02/2026
Published 20/02/2026
Publication Time 19 Days
2

Login


My IP

PlumX Metrics